• Earlier in January 2026, Alnylam Pharmaceuticals issued full-year 2026 guidance, projecting combined net product revenue of US$4.90 billion to US$5.30 billion, implying very large growth versus 2025 at the mid-point.
• This guidance signals management’s confidence in the commercial traction of its existing therapies and the scalability of its product portfolio.
• Next, we will examine how this very large step-up in expected 2026 net product revenue shapes Alnylam’s broader investment narrative.

We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

What Is Alnylam Pharmaceuticals' Investment Narrative?

To own Alnylam here, you really have to buy into the idea that RNAi can sustain a sizeable, durable commercial franchise, not just a one‑off run of launches. The new 2026 guidance, with expected combined net product revenue approaching US$5.00 billion, sharpens that belief by putting a very large step-up in sales front and center, and effectively turns execution on existing products into the key short term catalyst. It also raises the stakes: any stumble in adoption, pricing, reimbursement or manufacturing could now matter more than it did when expectations were lower. Layer on a premium price-to-sales multiple, recent share price pullback and some insider selling, and the risk/reward looks increasingly tied to whether this guidance proves achievable rather than aspirational.

However, there is one execution risk behind that revenue jump that investors should not overlook. Despite retreating, Alnylam Pharmaceuticals' shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Investors in the Simply Wall St Community place Alnylam’s fair value between US$315.96 and US$859.84 across 5 independent views, giving you a wide set of starting points. Set against management’s very large 2026 revenue ambition, these differing assumptions about execution, pricing and adoption can meaningfully shift how you think about the company’s future performance.

Explore 5 other fair value estimates on Alnylam Pharmaceuticals - why the stock might be worth over 2x more than the current price!

Build Your Own Alnylam Pharmaceuticals Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Alnylam Pharmaceuticals research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Alnylam Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alnylam Pharmaceuticals' overall financial health at a glance.

Looking For Alternative Opportunities?

Our top stock finds are flying under the radar-for now. Get in early:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.